The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I've been holding some of these shares for quite a while and see this as a positive piece of news. BAE are a huge company - much much bigger than Carrs - so for them to be buying this number of shares is fantastic news. They must see Carrs as a company on the up
Big Trade this morning - 400,000 shares at £63k, showing as a buy - hope it is as it will show confidence
Hey folks.
Haven’t been on here in a while as I haven’t been well. Severe back injury and loads of meds so I’ve been away with the fairies!
I bought in here over a year ago and am now showing a 56% loss! I don’t get it with this company - I mean I’m here for the long haul as I think these guys (certainly on the face of it) have a lot going for them, but this isn’t reflected in the share price, notwithstanding the current assault Coronavirus is having on the global market. But this should b Whig here than it is.
As I say, I’ve not been well for a while and am trying to catchup and have just been browsing the threads and it seems I’ve missed some stuff - some talk of a court hearing? Legal challenge for material breech by Beyond Air? Please could someone do a quick update for me, to catch me up? I’d be really grateful.
As Circassia specialises in breathing solutions, is Circassia able to help in anyway with the coronavirus outbreak?
Thnaks all
This is a really good RNS that demonstrates good revenue, solid performance and an excellent strategy going forward. I thought we would have seen a decent reaction with the SP
Couple big buys - nun of them mine tho'
Nothing on the horizon yet - just coldframes and sweet corn at the moment!
I think we need 1 share trade for positive codes dont we? Although I guess a 1000 share trade might mean really good news?!
Shame someone sold £75k's worth. Maybe you should find him too Rich and give him a good talking to too!!
Get the Hopping Hare out Rich! Nice punch that one - another local brewer to you too
If La Parilla is producing - and, more importantly, selling tungsten conecentrate, that means an income stream is being created. With LP's output at 220T per month and an expected 500T per year(?) at Regua, could he not borrow against that to jane the gold independently rather than a placing or JV to fund it?
No code yet RK - but things are stacking up for this company. We are expecting lots of news and I wonder if this pressure will gently ease the SP up?
"For those with Level 3 access (NASD), there’s some staggering BUY orders been placed… "
I don't have Level 3, RA, so what is this showing? How many are we talking about? What size transactions? Have these buys been placed with MM's and the price being held down until they're filled?
Or maybe not!
Here we go!!
Thanks for the feedback folks, really appreciate it.
Please can you point me in the direction of the 2018 annual report Ian? It's not on the website is it? Or am I being an eejit?!
SULK. Please can you explain what you mean by this? Why do you "smell a rat" with this trade? Thanks
B
Hi folks - I'm new here.
Bizarre! Two RNS's released confirming FDA approval at 3:34 - Tudorza and 3:58 Duaklir If you check the trades, folks somebody sold 273,914 @ 28 fo £76k!! Am I missing something? And look at all those other trades ....?
No, Kettle you're right and I understand. Was literally just wondering if they are a company that are spinning a few plates but if its just the one plate, I'll invest accordingly - more than happy to have a pre-minutes punt. Think its a bit odd though that they're not chasing EMA approval at the same time....
Hanibal - the reason I asked about strategy is to enquire as to what the plan might be if they don't get FDA approval. Company fold? Company placement to fund EMA approval? or Japanese? etc Or is it all over if the FDA say "no".
I've read it Hanibal. Read a lot of them, looked through their website and read the annual reports. None of them appear to answer all of the questions I have raised.
Thanks JB - appreciate your quick response. So have the board stated their strategy in an RNS or via any of their annual reports? I've just read the 2017 annual report strategies section and nothing mentioned. Do you know when Motif's E-o-Y is? When can we expect 2018 annual report?